Bausch Health Companies Beheer
Beheer criteriumcontroles 2/4
De CEO Bausch Health Companies is Tom Appio, benoemd in May2022, heeft een ambtstermijn van 2.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.88M, bestaande uit 7.4% salaris en 92.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 3.82M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 8.3 jaar.
Belangrijke informatie
Tom Appio
Algemeen directeur
US$15.9m
Totale compensatie
| Percentage CEO-salaris | 7.4% |
| Dienstverband CEO | 2.5yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 8.3yrs |
Recente managementupdates
Recent updates
There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise
Oct 10
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Sep 19Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%
Aug 062 Red Alerts On Bausch Health Companies
Jul 25The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
May 21Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
May 07Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02Bausch Health: Long-Term Need To Place Stops For Protection
Sep 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$471m |
| Mar 31 2024 | n/a | n/a | -US$455m |
| Dec 31 2023 | US$16m | US$1m | -US$592m |
| Sep 30 2023 | n/a | n/a | -US$963m |
| Jun 30 2023 | n/a | n/a | -US$186m |
| Mar 31 2023 | n/a | n/a | -US$357m |
| Dec 31 2022 | US$13m | US$1m | -US$225m |
| Sep 30 2022 | n/a | n/a | US$254m |
| Jun 30 2022 | n/a | n/a | US$43m |
| Mar 31 2022 | n/a | n/a | -US$407m |
| Dec 31 2021 | US$10m | US$854k | -US$948m |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$1b |
| Mar 31 2021 | n/a | n/a | -US$1b |
| Dec 31 2020 | US$4m | US$775k | -US$560m |
| Sep 30 2020 | n/a | n/a | -US$2b |
| Jun 30 2020 | n/a | n/a | -US$2b |
| Mar 31 2020 | n/a | n/a | -US$2b |
| Dec 31 2019 | US$4m | US$769k | -US$2b |
| Sep 30 2019 | n/a | n/a | -US$616m |
| Jun 30 2019 | n/a | n/a | -US$917m |
| Mar 31 2019 | n/a | n/a | -US$2b |
| Dec 31 2018 | US$4m | US$730k | -US$4b |
| Sep 30 2018 | n/a | n/a | -US$3b |
| Jun 30 2018 | n/a | n/a | -US$2b |
| Mar 31 2018 | n/a | n/a | -US$805m |
| Dec 31 2017 | US$3m | US$650k | US$2b |
Compensatie versus markt: De totale vergoeding ($USD 15.88M ) Tom } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.59M ).
Compensatie versus inkomsten: De vergoeding van Tom is gestegen terwijl het bedrijf verliesgevend is.
CEO
Tom Appio (62 yo)
2.5yrs
Tenure
US$15,878,578
Compensatie
Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$15.88m | 0.12% $ 3.8m | |
| Executive VP & General Counsel | 2.5yrs | US$3.16m | 0.035% $ 1.1m | |
| Executive VP & CFO | less than a year | geen gegevens | geen gegevens | |
| Executive VP & COO | 2.8yrs | geen gegevens | 0.035% $ 1.1m | |
| VP & Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP and Chief HR & Communications Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Europe & Canada | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Ortho Dermatologics | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Solta Medical | 1.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of US Pharma | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Treasurer | no data | geen gegevens | geen gegevens |
2.5yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BHC wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$15.88m | 0.12% $ 3.8m | |
| Independent Chairman | 2.4yrs | US$812.50k | 0.000060% $ 1.9k | |
| Independent Director | 16.3yrs | US$389.55k | 0.0018% $ 57.7k | |
| Chairman of External Advisory Board | no data | US$2.00m | geen gegevens | |
| Independent Director | 8.3yrs | US$718.28k | 0% $ 0 | |
| Member of the External Advisory Board | 15.7yrs | geen gegevens | geen gegevens | |
| Member of the External Advisory Board | 15.7yrs | geen gegevens | geen gegevens | |
| Member of the External Advisory Board | 15.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 3.7yrs | US$691.72k | 0.00020% $ 6.4k | |
| Independent Director | 8.4yrs | US$377.50k | 0.011% $ 369.2k | |
| Independent Director | 3.7yrs | US$381.31k | 0.031% $ 988.8k | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
8.3yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BHC wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).